1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- PAFSC 1st Committee to Review Liovel, Nexium
April 25, 2011
- FJPWA May Have to Consider Rotational Operations: FJPWA President Bessho
April 25, 2011
- Korosho Draws up GL for R&D Use of Donated Blood
April 25, 2011
- No Remarkable Increases in Infections in Disaster-hit Areas: NIID
April 25, 2011
- Japan Should Join PIC/S to Harmonize Its GMP with Global Standards: Dr Sakurai of PMDA
April 25, 2011
- Teijin Pharma Announces New Global Partners for TMX-67
April 25, 2011
- DSP's Pharmacist Employees Volunteer to Assist in Disaster Area
April 25, 2011
- Nomura Securities Predicts Plummeting Profitability for Daiichi Sankyo's Pravastatin
April 25, 2011
- PMDA to Provide Consultation Services for Wider Range of OTC Drugs
April 25, 2011
- Yakult Licenses Resminostat from 4SC of Germany
April 25, 2011
- Korosho Publishes Medical Societies' Views on Switch OTC Drug Candidates
April 25, 2011
- Gov't to Enforce 25% Power Cuts This Summer for Major Users Including Drug Makers
April 18, 2011
- Gov't Appeals to High Court in Iressa Case
April 18, 2011
- Taisho Acquires Hoepharma of Malaysia
April 18, 2011
- Korosho Calls on Industry to Come Up with Energy Conservation Plans
April 18, 2011
- FDA Approves 1st New Treatment for Late-stage Melanoma in Over a Decade: BMS
April 18, 2011
- Eiken Licenses LAMP Technology to OptiGene
April 18, 2011
- ASKA Begins Shipments of Thyradin Substitute
April 18, 2011
- Review Period for QAB149 for COPD Extended 3 Months by FDA
April 18, 2011
- MCM Negotiates Partnership with Clearstone of Canada in CLS Services
April 18, 2011
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…